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The von Hippel-Lindau (pVHL) protein plays an important role in hypoxia sensing. It binds to the hydroxylated
hypoxia-inducible factor 1a (HIF-1a) and serves as a recognition component of an E3-ubiquitin ligase complex.
In hypoxia or secondary to a mutated VHL gene, the nondegraded HIF-1a forms a heterodimer with HIF-b and
leads to increased transcription of hypoxia-inducible genes, including erythropoietin (EPO). The autosomal domi-
nant cancer-predisposition von Hippel-Lindau (VHL) syndrome is due to inheritance of a single mutated allele of
VHL. In contrast, we recently showed that homozygous germline 598CrT VHL mutation leads to Chuvash poly-
cythemia (CP). We subsequently found VHL mutations in three unrelated individuals unaffected with CP, one of
whom was compound heterozygous for the 598CrT mutation and another VHL mutation. We now report seven
additional polycythemic patients with VHL mutations in both alleles. Two Danish siblings and another American
boy were homozygous for the VHL 598CrT mutation. Three unrelated white Americans were compound heter-
ozygotes for 598CrT and another VHL mutation, 562CrG in two and 574CrT in the third. Additionally, a
Croatian boy was homozygous for a 571CrG VHL mutation, the first example of homozygous VHL germline
mutation causing polycythemia, other than the VHL 598CrT mutation. We have not observed VHL syn-
drome–associated tumors in polycythemic subjects or their heterozygous relatives; however, this will need to be
evaluated by longitudinal studies. Over all, we found that up to half of the consecutive patients with apparent
congenital polycythemia and increased serum Epo we have examined have mutations of both VHL alleles. Those
findings, along with reports of CP, underscore that VHL mutations are the most frequent cause of congenital
polycythemia and define a new class of polycythemic disorder, polycythemias due to augmented hypoxia sensing.
The von Hippel-Lindau protein (pVHL) plays a crucial
role in hypoxia sensing (Semenza 2001). pVHL binds to
the hydroxylated form of the hypoxia-inducible factor
1a (HIF-1a) and serves as the recognition component
of an E3-ubiquitin ligase complex that comprises elon-
gins B and C, cullin 2, and ring-box 1 (Epstein et al.
2001; Ivan et al. 2001; Jaakkola et al. 2001). In hypoxia,
or as a result of a mutated VHL, the accumulation of
the nondegraded HIF-1a leads to the formation of a
heterodimer with HIF-b and the activation of an array
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of hypoxia-inducible genes, including erythropoietin
(EPO) (see fig. 1; Semenza 2001). The cancer-predis-
position von Hippel-Lindau syndrome (MIM 193300)
is an autosomal dominant disorder due to inheritance
of a mutation in a single VHL allele. Faithful to Knud-
son’s two-hit hypothesis (Knudson et al. 1975), tumors
develop upon somatic mutation or inactivation of the
other, normal VHL allele. However, until the recent mo-
lecular elucidation of the cause of Chuvash polycythemia
(CP) or autosomal recessive benign congenital polycy-
themia (MIM 263400), true inheritance of germline mu-
tations in both VHL alleles, to our knowledge, had never
been reported.
There are numerous causes for an increased red-
blood-cell mass, or “polycythemia.” Polycythemia can
be either acquired or congenital. Primary polycythemias
have low serum Epo and are due to somatic or germline
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Figure 1 Hypoxia-sensing pathway. The hypoxia-inducible factor 1a (HIF-1a) is a master regulator of hypoxia. In normoxia, HIF-1a is
hydroxylated by proline hydroxylase; pVHL binds to the hydroxylated form of HIF-1a and serves as the recognition component of an E3-
ubiquitin ligase complex that comprises elongins B (B) and C (C), Cullin 2, and ring-box 1; this includes a proteosomal degradation of HIF-
1a. In hypoxia, HIF-1a accumulates and forms a heterodimer with HIF-1b that will bind to hypoxia-responsive elements (HRE) and leads to
an increased synthesis of the related hypoxia-responsive genes, such as EPO, vascular endothelial growth factor (VEGF), glucose transporter
1 (Glut1), phospho-glycerate kinase (PGK), transferrin and its receptor, and other genes.
mutations expressed within the erythroid progenitors. In
contrast, increased circulating level of erythropoiesis-
stimulating substance, typically Epo, leads to secondary
polycythemias (Prchal 2003). CP is a unique polycy-
themic disorder, the only recessively inherited disorder,
and endemic in the Chuvash Autonomous Republic of
Russia (Sergeyeva et al. 1997; Ang et al. 2002b). We
recently demonstrated that CP was caused by homo-
zygosity for the 598CrT (R200W) VHL mutation (Ang
et al. 2002a, 2002b). Subsequently, we have found VHL
mutations in three unrelated non-Chuvash children; of
those three children, one was a compound heterozygote
for the VHL 598CrT mutation and a VHL 388GrC
(V130L) mutation in the other allele (Pastore et al.
2003). Homozygosity for the VHL 598CrT mutation
was also recently observed in three Bangladesh families
living in the United Kingdom (Percy et al. 2002).
We pursued the hypothesis that inheritance of the
VHL mutation is an important cause of congenital poly-
cythemia. Patients were referred to our laboratory by
pediatric hematologists and other clinical collaborators.
Thirteen patients were selected and evaluated because
of their history of sporadic, apparently congenital poly-
cythemia and “a normal” (considered as an inappro-
priate level for the elevated hemoglobin level) or elevated
serum Epo; all patients except two siblings were unre-
lated. Patients were of various ethnic backgrounds; none
of them were of Chuvash origin. All patients signed an
informed consent for the study that had been reviewed
and approved by the institutional review board of Baylor
College of Medicine. One stored specimen was previ-
ously collected with approval of the internal review
board of University of Alabama at Birmingham. Periph-
eral blood from patients, and, in most instances, also
from their available relatives were collected in acid-cit-
rate-dextrose, and genomic DNA samples were isolated
by use of a QIAamp DNA blood mini kit (QIAGEN).
To search for VHL mutations, we proceeded to a sys-
tematic sequencing of all three VHL exons and intron-
exon boundaries. PCR reactions were performed in 50-
ml volume that contained 20 mM Tris-HCl pH 8.4, 50
mM KCl, 1.5 mM MgCl2, 100 mM dNTP, 300 nM prim-
ers, and 2.5 U/reaction Taq DNA polymerase (Life Tech-
nologies). The following sets of primers were used:
VHL1F 5′-CGAAGACTATGGAGGTCGAC-3′, VHL1R
5′-GGCTTCAGACCGTGCTATCG-3′ for exon 1;
VHL2F 5′-GTGTGGCTCTTTAACAACC-3′, VHL2R 5′-
CTGTACTTACCACAACAACC-3′ for exon 2; and
VHL3F 5′-CCTTGTACTGAGACCCTAG-3′, VHL3R 5′-
GCTGAGATGAAACAGTGTA-3′ for exon 3. DMSO
(10%) was added for amplification of exon 1. PCR prod-
ucts were then purified with a QIAquick Gel Extraction
Kit (QIAGEN). Ten to 20 ng of purified PCR product
was used as the template for sequencing with a DNA
Sequencing Kit (BigDye Terminator Cycle Sequencing
Ready Reaction, Applied Biosystems), with forward or
reverse primers (identical to those used for PCR reaction).
The sequencing reaction was performed in the Peltier
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Table 1
Patient Characteristics
Patient Sex
Age Pa
(years)
Age Stb
(years) Hgc Hctd Epoe Ethnic Origin VHL Mutations Remarks
1 M 1 14 20.8 64 N-Hf Danish R200W/R200W Sibling of patient 2
2 M 5 12 19.5 56 N-Hf Danish R200W/R200W Sibling of patient 1
3 M 3 19 16.4 53.2 N White American R200W/R200W Thrombosis
4 M 9 10 23.5 70.2 H White American R200W/P192A …
5 F 5 13 16.3 51.6 N White American R200W/L188V …
6 M 5 15 21 58.7 H White American R200W/L188V Lost of follow-up
7 M 1 17 18 61 H Croatian H191D/H191D …
a Age P p age at presentation.
b Age St p age at which we studied the patient.
c Hg p hemoglobin.
d Hct p hematocrit.
e Hp high; Np normal (since several independent laboratories at local institutions performed serum Epo measurement
and had different normal ranges).
f Patient 1 and patient 2 had their serum Epo measured several times; the serum Epo was high once and at normal-to-
high–normal range on other occasions.
Model P200 thermocycler. The products were then ana-
lyzed on the ABI Prism 377 DNA Sequencer (Applied
Biosystems) according to the manufacturer’s protocol.
Of the 13 patients analyzed, 7 were found to have
VHL mutations; all 7 had both VHL alleles mutated
(see table 1). Eleven of 13 tested subjects had the EPOR
gene analyzed for mutation (Kralovics et al. 2001); none
was found.
Patient 1 and patient 2, two healthy Danish siblings,
and another, unrelated white boy from the United States
(patient 3) were all homozygous for the 598CrT VHL
mutation. Both Danish siblings had been diagnosed in
early childhood (patient 1 was incidentally found po-
lycythemic while hospitalized because of wheezing at age
8 mo). Evaluation of family members revealed polycy-
themia in his otherwise-asymptomatic brother (patient
2); no other family members were found to be polycy-
themic (see pedigree [fig. 2A]; table 1).
Patient 3 had incidentally been found to be polycy-
themic on day 3 of life and had been treated by occa-
sional phlebotomies since then. At age 15 years, he was
hospitalized for severe abdominal pain and was found
to have infarction of the great omentum secondary to a
mesenteric thrombosis. He later had deep venous throm-
bosis complicated by pulmonary embolism at age 18
years. He has been on anticoagulation therapy with war-
farin and remains polycythemic (age 19 years). No ev-
idence for intra-abdominal tumors or cystic lesions was
found by abdominal CT scan or during abdominal
surgery.
Patient 4, patient 5, and patient 6 (two white Amer-
ican males and one white American female) were found
to be compound heterozygous for the 598CrT mutation
and another VHL mutation. Patient 4 had been diag-
nosed with polycythemia at age 9 years; he is a com-
pound heterozygote for the VHL 598CrT mutation and
a previously undescribed 574CrT (P192A) VHL mu-
tation. Analysis of family members revealed that the
VHL 598CrT mutation had been inherited from his
mother, whereas the 574CrT mutation was inherited
from his father and also found in his brother; they were
not polycythemic (see fig. 2B).
Patient 5 is a 13-year-old girl incidentally found to
have polycythemia at age 5 years, the first time her he-
moglobin concentration was tested; she has a mild club-
bing without any other symptoms or stigmata of poly-
cythemia and has been treated with periodic phle-
botomies. This girl is a compound heterozygote for the
598CrT and 562CrG (L188V) VHL mutations. The
598CrT mutation had been inherited from her mother.
The inheritance of the 562CrG mutation could not be
determined, as we were unable to obtain consent from
other family members and her undisclosed father.
Patient 6 was diagnosed with polycythemia at age 5
years; he had been previously reported as having sec-
ondary polycythemia because of a markedly increased
serum Epo (Mankad et al. 1987). The patient was sub-
sequently evaluated in our laboratory 15 years ago: (a)
in vitro evaluation of erythroid progenitors responses to
Epo after careful removal of serum from erythroid pro-
genitors could not confirm the reported Epo independ-
ence, (b) sequencing of EPO cDNAs revealed no mu-
tations, and (c) the etiology of his polycythemic disorder
remained unclear at that time (J. T. Prchal, unpublished
data). Recent re-examination of his stored sample for
the VHL mutation revealed the same mutations as in
patient 5: a 598CrT mutation and a 562CrG VHL
mutation; it is unfortunate that we have not been able
to locate him. Subject 5 and subject 6 were not related
and originate from central Tennessee and southern Al-
abama, respectively.
Patient 7 is a 17-year-old Croatian male who was
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Figure 2 Pedigree of families available for DNA studies and with more extended family history. A, Pedigree of patient 1 and patient 2.
Asterisks (*) denote that family members of patient 1 (Pt. #1) and patient 2 (Pt. #2) had developed the following complications: 1:2 had history
of brain tumor, whereas 2:2 had history of ocular thrombosis. B, Pedigree of patient 4. C, Pedigree of patient 7.
diagnosed with polycythemia and elevated serum Epo
in early childhood. He was found to be homozygous for
a previously undescribed 571CrG (H191D) VHL mu-
tation. The 571CrG mutation can be distinguished
from other alleles, as it abolishes the MslI restriction
site. The parents of patient 7 were unrelated. They and
his sister were heterozygous for the 571CrG (H191D)
VHL mutation (see fig. 2C). We then screened 179 nor-
mal control subjects (DNA kindly provided by the Bay-
lor College of Medicine Polymorphism Resource Core,
comprising 48 whites, 43 African American, 40 Asians,
and 48 Hispanics), and all had normal MslI restriction
pattern. Thus, the 571CrG mutation likely represents
a disease-causing mutation, and it is not a common poly-
morphism. Our discovery of homozygosity for the
571CrG (H191D) mutation is the first example, to our
knowledge, of a homozygous germline VHL mutation
other than the VHL 598CrT mutation causing poly-
cythemia. The exact phenotype of the 571CrG VHL
mutation will need to be defined by longitudinal studies.
In the six remaining patients with a similar polycy-
themic phenotype, no VHL mutations were found. With
the exception of subject 3, all polycythemic patients had
no medical problem; some, but not all, polycythemic
subjects gave a history of headaches and difficulty in
concentrating when their hematocrit (Hct) was high,
and, in some, these symptoms were immediately relieved
by phlebotomy. On the basis of our observation, it ap-
pears that mutation of the VHL gene is an important
cause for congenital polycythemia. Combined with our
previous data (Pastore et al. 2003), up to 50% of pa-
tients with apparent congenital polycythemia and ele-
vated serum Epo (11 of 21 patients analyzed so far)
appear to have mutation in the VHL gene. The phe-
notype of this polycythemic disorder may comprise an
increased risk for thrombosis. Although this complica-
tion was observed in only one of our patients (patient
3), preliminary report of an epidemiological study in the
Chuvash population had reported an increased risk for
thrombosis possibly associated with homozygosity for
the 598CrT VHL mutation (Gordeuk et al. 2001).
Inheritance of a mutation in the VHL tumor sup-
pressor is known to predispose to the high risk for vari-
ous tumors (Richards et al. 1998; Friedrich 2001).
Through studies of families with VHL syndrome, ge-
notype-phenotype correlation has emerged. Families
with VHL are usually differentiated on the basis of their
risk for pheochromocytomas: low risk for families with
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type 1 VHL and high risk for families with type 2 VHL.
Type 2 VHL is further divided into a low (type 2A) or
high (type 2B) risk for renal cell carcinoma, whereas
families with type 2C present only with familial pheo-
chromocytomas. Type 2 VHL is generally associated
with missense VHL mutations, whereas type 1 VHL mu-
tations tend to have loss-of-function mutations of the
VHL gene, which are frequently deletions or truncated
mutations (Friedrich 2001). In our families, we would
therefore expect to observe not only a high incidence for
pheochromocytomas and/or renal cell carcinoma, but
possibly other VHL-associated tumors, as well. To
evaluate this, all patients with identified VHL mutations
except patient 6 were subject to evaluation on the basis
of recommendations, developed by the National Insti-
tutes of Health, that comprise abdominal and cerebral
imaging and ophthalmologic examination (Choyke
1995). To our surprise, no VHL tumors were observed,
although MRI of spinal cord was not performed on every
child. We then reviewed history and medical records of
11 subjects heterozygous for the VHL mutations de-
scribed here (three heterozygotes for the 571CrG mu-
tation, seven for the 598CrT mutation, and two for the
574CrT VHL mutation), three heterozygotes for the
previously reported 388GrC mutation (Pastore et al.
2003), as well as 27 Chuvash subjects heterozygous for
the VHL 598CrT mutation (Ang et al. 2002a, 2002b).
None of these studied heterozygote carriers had any
VHL syndrome–associated tumors, though we could not
exclude a possible VHL-associated tumor in the Danish
family in which one man had a history of otherwise-
uncharacterized brain tumor and another had a history
of ocular thrombosis. However, both these two ancestors
of patient 1 and patient 2 were older than age 70 years
(see fig. 2A), their DNA was not available for testing,
and these medical disorders likely represent sporadic tu-
mors unrelated to VHL syndrome. One VHL mutation,
562CrG, observed in our polycythemic subjects has
been reported to have a high risk for pheochromocytoma
development and to be associated with families with type
2C VHL syndrome (Ritter et al. 1996). We have been
unable to locate heterozygous relatives of our polycy-
themic subjects who carry this VHL mutation. The
388GrC mutation, another VHL mutation previously
reported in compound heterozygosity with the 598CrT
mutation (Pastore et al. 2003), has also been reported
as a germline mutation in two patients with VHL syn-
drome (Universal VHL-Mutation Database). Yet, the
consequences of the association of the VHL 562CrG
mutation or the 388GrC mutation with the VHL
598CrT mutation in the compound heterozygous pro-
positus will need to be evaluated prospectively, and the
low penetrance of these tumors and the young age of
the patients we studied cannot exclude a possible VHL
tumor association at this point.
The absence of tumors in our families is in keeping
with the results of an ongoing epidemiological study in
the Chuvash population that failed to demonstrate an
increased risk of the VHL 598CrT mutation for VHL
syndrome–associated tumors (Gordeuk et al. 2001).
VHL syndrome is known to have variable penetrance,
and tumor development may also be influenced by other
genetic or environmental factors, such as carcinogen ex-
posure (Bruning et al. 1997; Webster et al. 1998). Fur-
thermore, certain mutations, such as the VHL 505TrC
mutation, may even confer an advanced-age penetrance
of tumor development (Bender et al. 2001). Therefore,
longitudinal studies will be necessary to determine the
exact risk of tumor development in our patients. Al-
though as yet unconfirmed, this apparent low penetrance
for tumor development contrasts with a highly penetrant
polycythemic phenotype in all patients with homozy-
gosity or compound heterozygosity for those VHL mu-
tations we discuss here.
It is of interest that patients with the mutations in the
VHL gene reported here do not appear at risk of devel-
oping tumors; however, this will need to be confirmed by
longitudinal studies as well as studies including adults
who have these VHL mutations. Our findings emphasize
a distinction between VHL “polycythemia-causing” mu-
tations and other VHL mutations associated with the tu-
mor-predisposition syndrome. The 571CrG, 562CrG,
and 574CrT VHL mutations found in compound
heterozygosity with the VHL 598CrT mutation could
be considered “polycythemia-associated” mutations.
Whether homozygosity for those mutations would also
lead to a polycythemic phenotype remains to be deter-
mined. Both VHL-polycythemia–causing” mutations
(571CrG and 562CrG) and most of the “polycythe-
mia-associated” mutations (i.e., 388GrC, 562rG, and
574CrT) are missense mutations localized in the C-ter-
minal portion of VHL. Moreover, both “polycythemia-
causing” mutations and “polycythemia-associated” mu-
tations are located within the same structural region (see
fig. 3). Further, the 376GrT (D126Y) VHL mutation,
recently reported as a possible autosomal dominant pol-
ycythemia-causing mutation found in two siblings (Pas-
tore et al. 2003), is localized within the same domain
(see fig. 3). This domain is distinct from the region di-
rectly interacting with elongins B and C (Ohh et al.
1999) and from the VHL beta domain known to interact
with HIF-1a (Ohh et al. 2000). The ability of the
562CrG VHL mutant to interact with elongin B and
C, as well as to capture and ubiquinate HIF-1a, was
shown to be similar to the wild-type VHL (Clifford et
al. 2001). Similarly, the VHL 598CrT mutation was
shown to lead to only a mild decrease in its ability to
capture HIF-1a (Ang et al. 2002b). It is therefore con-
ceivable that those mutations cause only a modest im-
pairment of HIF-1a degradation. Alternatively, it is pos-
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Figure 3 VHL-polycythemia–causing and polycythemia-associated mutations. Illustration of VHL protein structure (yellow) and inter-
actions with elongin B (pale blue), elongin C (dark blue), and HIF-1a (green) was produced by use of Swiss PDB-viewer software and was
based on the PDB-1LM8 crystallized structure (Min 2002). Red, Homozygous VHL mutations found at position R200 and H191. Orange,
VHL mutations found in compound heterozygosity with the 598CrT (R200W) mutation. Pink, Mutation at Y126, previously proposed as a
dominant negative VHL mutation found in two siblings with apparent congenital polycythemia (Pastore et al. 2003).
sible that those mutations alter the interaction of VHL
with other proteins, such as fibronectin, which was ob-
served with the L188V mutation (Hoffman et al. 2001),
perhaps resulting in the tissue-specific effect that may be
more expressed in Epo-producing tissues and the ery-
throid cells. It is interesting that the 376GrT, 388GrC,
562CrG, 574CrT, and 598CrT VHL mutations dis-
cussed here are encoding for amino acids that are con-
served between mouse and human; however, the
571CrG mutation is not (Gao et al. 1995). Only two
mutations (the 388GrC and 562CrG VHL mutations)
affect highly conserved amino acids, when comparing
human and Drosophila VHL protein (Adryan et al.
2000). In conclusion, we show here that inheritance of
mutations of both alleles of the VHL gene represents an
important cause of congenital polycythemia. We report
that about one-half of patients with apparent congenital
polycythemia and increased or inappropriate serum Epo
(11 of 21) have VHL mutations. In our experience, mu-
tations of both alleles of the VHL gene are the most
common of all congenital polycythemias with the de-
fined molecular defect so far (Prchal 2003) and are com-
patible with long-term survival. In contrast to VHL syn-
drome, this congenital disorder appears to be associated
with a low penetrance for cancer development. The VHL
mutations define a new category of polycythemic dis-
order: polycythemias due to inherited augmentation of
hypoxia sensing.
Acknowledgments
This work is supported by grants R01HL66333-01 and
R01HL5007-08 from the National Heart, Lung, and Blood
Institute of the National Institutes of Health. We are indebted
418 Am. J. Hum. Genet. 73:412–419, 2003
to our clinical collaborators who referred patients and pro-
vided the clinical material: Dr. Thomas Thelle, James Whit-
lock, Deborah Smith, and Helmuth Gardner.
Electronic-Database Information
URLs for data presented herein are as follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for Chuvash polycythemia and
VHL syndrome)
Protein Data Bank, http://www.rcsb.org/pdb/ (for the structure
of Hif-1a-Pvhl-Elonginb-Elonginc Complex: PDB-1LM8)
Swiss PDB viewer, http://us.expasy.org/spdbv/
Universal VHL-Mutation Database, http://www.umd.necker
.fr:2005/)
References
Adryan B, Decker HJ, Papas TS, Hsu T (2000) Tracheal de-
velopment and the von Hippel-Lindau tumor suppressor
homolog in Drosophila. Oncogene 19:2803–2811
Ang SO, Chen H, Gordeuk VR, Sergueeva AI, Polyakova LA,
Miasnikova GY, Kralovics R, Stockton DW, Prchal JT
(2002a) Endemic polycythemia in Russia: mutation in the
VHL gene. Blood Cells Mol Dis 28:57–62
Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y,
Liu E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH,
Stockton DW, Semenza GL, Prchal JT (2002b) Disruption
of oxygen homeostasis underlies congenital Chuvash poly-
cythemia. Nat Genet 32:614–621
Bender BU, Eng C, Olschewski M, Berger DP, Laubenberger
J, Altehofer C, Kirste G, Orszagh M, van Velthoven V, Mios-
czka H, Schmidt D, Neumann HP (2001) VHL c.505 TrC
mutation confers a high age related penetrance but no in-
creased overall mortality. J Med Genet 38:508–514
Bruning T, Weirich G, Hornauer MA, Hofler H, Brauch H
(1997) Renal cell carcinomas in trichloroethene (TRI) exposed
persons are associated with somatic mutations in the von
Hippel-Lindau (VHL) tumour suppressor gene. Arch Toxi-
col 71:332–335
Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan
WM, Zbar B (1995) von Hippel-Lindau disease: genetic, clin-
ical, and imaging features. Radiology 194:629–642
Clifford SC, Cockman ME, Smallwood AC, Mole DR, Wood-
ward ER, Maxwell PH, Ratcliffe PJ, Maher ER (2001) Con-
trasting effects on HIF-1alpha regulation by disease-causing
pVHL mutations correlate with patterns of tumourigenesis in
von Hippel-Lindau disease. Hum Mol Genet 10:1029–1038
Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke
J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda
A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead
R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Rat-
cliffe PJ (2001) C. elegans EGL-9 and mammalian homologs
define a family of dioxygenases that regulate HIF by prolyl
hydroxylation. Cell 107:43–54
Friedrich CA (2001) Genotype-phenotype correlation in von
Hippel-Lindau syndrome. Hum Mol Genet 10:763–737
Gao J, Naglich JG, Laidlaw J, Whaley JM, Seizinger BR, Kley
N (1995) Cloning and characterization of a mouse gene with
homology to the human von Hippel-Lindau disease tumor
suppressor gene: implications for the potential organization
of the human von Hippel-Lindau disease gene. Cancer Res
55:743–747
Gordeuk VR, Sergueeva AI, Miasnikova GY, Okhotin DJ,
Prchal JT, Polyakova LA (2001) High mortality due to
thrombosis and cerebral hemorrhage in Chuvash polycy-
themia. Blood 98:224
Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG
Jr (2001) von Hippel-Lindau protein mutants linked to type
2C VHL disease preserve the ability to downregulate HIF.
Hum Mol Genet 10:1019–1027
Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic
A, Asara JM, Lane WS, Kaelin WG Jr (2001) HIFa targeted
for VHL-mediated destruction by proline hydroxylation: im-
plications for O2 sensing. Science 292:464–468
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell
SJ, Kriegsheim AV, Hebestreit HF, Mukherji M, Schofield
CJ, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Targeting
of HIF-a to the von Hippel-Lindau ubiquitylation complex
by O2-regulated prolyl hydroxylation. Science 292:468–472
Knudson AG Jr, Hethcote HW, Brown BW (1975) Mutation
and childhood cancer: a probabilistic model for the inci-
dence of retinoblastoma. Proc Natl Acad Sci USA 72:5116–
5120
Kralovics R, Josef T, Prchal JT (2001) Genetic heterogeneity
of primary familial and congenital polycythemia. Am J He-
mat 68:115–121
Mankad VN, Moore RB, McRoyan D, Zuckerman K (1987)
Erythrocytosis associated with spontaneous erythroid colony
formation and idiopathic hypererythropoietinemia. J Pediatr
111:743–745
Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich
NP (2002) Structure of an HIF-1a-pVHL complex: hydrox-
yproline recognition in signaling. Science 296:1886–1889
Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang
LE, Pavletich N, Chau V, Kaelin WG (2000) Ubiquitination
of hypoxia-inducible factor requires direct binding to the b-
domain of the von Hippel-Lindau protein. Nat Cell Biol 2:
423–427
Ohh M, Takagi Y, Aso T, Stebbins CE, Pavletich NP, Zbar B,
Conaway RC, Conaway JW, Kaelin WG Jr (1999) Synthetic
peptides define critical contacts between elongin C, elongin
B, and the von Hippel-Lindau protein. J Clin Invest 104:
1583–1591
Pastore YD, Jelinek J, Ang S, Guan Y, Liu E, Jedlickova K,
Krishnamurti L, Prchal JT (2003) Mutations in the VHL
gene in sporadic apparently congenital polycythemia. Blood
101:1591–1595
Percy MJ, McMullin MF, Treacy M, Potter M, Watson WH,
Jowitt SN, Lappin TRJ (2002) Identification of the Chuvash-
type congenital polycythemia in patients of Asian and West-
ern European ancestry. Blood 100:660
Prchal JT. Classification and molecular biology of poly-
cythemias (erythrocytoses) and thrombocytosis. Med Clin
North Am (in press)
Richards FM, Webster AR, McMahon R, Woodward ER, Rose
S, Maher ER (1998) Molecular genetic analysis of von Hip-
pel-Lindau disease. J Intern Med 243:527–533
Ritter MM, Frilling A, Crossey PA, Hoppner W, Maher ER,
Reports 419
Mulligan L, Ponder BA, D Engelhardt (1996) Isolated fa-
milial pheochromocytoma as a variant of von Hippel-Lindau
disease. J Clin Endocrinol Metab 81:1035–1037
Semenza GL (2001) HIF-1 and mechanisms of hypoxia sens-
ing. Curr Opin Cell Biol 13:167–171
Sergeyeva A, Gordeuk VR, Tokarev YN, Sokol L, Prchal JF,
Prchal JT (1997) Congenital polycythemia in Chuvashia.
Blood 89:2148–2154
Webster AR, Richards FM, MacRonald FE, Moore AT, Maher
ER (1998) An analysis of phenotypic variation in the familial
cancer syndrome von Hippel-Lindau disease: evidence for
modifier effects. Am J Hum Genet 63:1025–1035
